Category Archives: Business and Investments

Latest From Business and Investments

SPARKs Fly When Stanford Profs Talk BD with Industry Leads

TheHill

5:30 PM, October 8th, 2014. Li Ka Shing Learning & Knowledge Center, Stanford University. Stanford’s SPARK Seminar Series provides a forum where BD leads can meet with aspiring academics to foster better collaboration and tech transfer. That said, much of the forum’s discussion has applicability outside of academia as well. Today Kanad Das (no relation), Associate Director of Partnering and Alliance Management at SPARK, has assembled a dream team of industry business development frontrunners to Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Investor Forum Closing Plenary: How Fragile is the Biotech Rally After Five Positive Years?

2

Last week’s 13th Annual BIO Investor Forum closed on Wednesday with a plenary session asking, “How fragile is the biotech rally after five positive years?” Moderated by Todd Foley, Managing Director, MPM Capital, the panel included: Rachel King, CEO, GlycoMimetics and Chair, BIO Ellen Lubman, VP Strategy and Innovation, Forest Laboratories Vijay Murthy, Director, Ventures and Early Stage Collaborations, AbbVie Michael A. Margolis, RPh, Managing Director, ROTH Capital Partners Doug Fambrough, PhD, CEO, Dicerna Pharmaceuticals Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Answering the Call for Cures in Michigan

21st-Century-Cures--Free

This week, the Kalamazoo Gazette published an op-ed on how we can accelerate the discovery, development and delivery of treatments and cures for patients written by Stephen Rapundalo, President and CEO of MichBio, and BIO’s Jim Greenwood. The op-ed highlights the focus of roundtable discussions being held across the country as part of the 21st Century Cures Initiative. The U.S. House of Representatives’ Energy and Commerce Committee launched the initiative – led by Chairman Fred Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Biotech CEOs Talk JOBS Act and IPO Experiences at 2014 BIO Investor Forum

Biotech IPOs Infographic

The JOBS Act has contributed to a dramatic acceleration in new biotech IPOs since its passage, with nearly a tripling in the rate of companies going public in the industry. By changing how entrepreneurs can access and communicate with investors earlier in the process, the JOBS Act has fundamentally shifted how CEOs of discovery-driven companies must spend their time dealing with internal versus external priorities. Yesterday at the 2014 BIO Investor Forum, a panel of Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Investor Forum Company Snapshot: Syntrix Biosystems

SyntrixBioLogo_3D

1.     What is your company’s lead product or technology? Omnitram (O-desmethyltramadol) is a novel  oral analgesic developed by Syntrix that alleviates pain via a dual mechanism involving mu-opioid receptor activation and inhibition of the reuptake of norepinephrine.  Omnitram is in clinical development and has just completed a Phase 1b double-blind, placebo-controlled clinical trial (N=40) in experimental pain. 2.     What sets your company apart from competitors? Omnitram is a proprietary solution for pain relief that is Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,